Improved
6112 HealthChanged
3785 LivesSaved
3568 Lives0 lives impacted in the last 24 hrs Learn More
A review of the proposed diabetes drug saxagliptin has been extended from April 30 until July 30 by the U.S. Food and Drug Administration. The companies developing the drug, Bristol Myers Squibb and AstraZeneca, requested the extension.
Earlier this month, an FDA panel of outside medical experts determined that the drug doesn't carry an excess cardiovascular risk, the Wall Street Journal reported.
Saxagliptin is a type of drug called a DPP-4 inhibitor that's designed to increase levels of so-called incretin hormones in order to help lower blood glucose levels. The only DPP-4 drug currently on the market in the United States is Merck and Co.'s Januvia.
Late last year, the FDA said drug makers would have to conduct more stringent clinical trials for type 2 diabetes drugs in order to better assess the drugs' heart attack and stroke risks, the Journal reported.
Add a Comment1 Comments
The only DPP-4 drug currently on the market in the United States is Merck and Co.'s Januvia.
November 30, 2009 - 3:42amdiscount cialis
cialis
cialis discount
discount cialis online
brand levitra
brand cialis
brand viagra
This Comment